# Non-small Cell Lung Cancer; NSCLC FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/non-small-cell-lung-cancer-nsclc

> 22 upcoming FDA catalysts in non-small Cell Lung Cancer; NSCLC: sacituzumab tirumotecan (MRK) on May to Aug 2027 (topline data readout); sacituzumab tirumotecan (MRK) on May 2027 (primary completion); LUMYKRAS™ (sotorasib, AMGN) on Jun to Sep 2027 (topline data readout); LUMYKRAS™ (sotorasib, AMGN) on June 2027 (primary completion); and 18 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 30, 2025 | [TEVIMBRA® (tislelizumab) primary completion](https://sec-api.dev/pdufa/tislelizumab) | ONC | Non-small Cell Lung Cancer; NSCLC | withdrawn | "NCT04746924 (A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor BeiGene; Results First Posted 2026-05-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04746924)) |
| February 23, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | NVCR | Non-Small Cell Lung Cancer (NSCLC) | withdrawn | "NCT06558799 (LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-02-23 (ACTUAL); Lead Sponsor NovoCure GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06558799)) |
| May to Aug 2027 | [Sacituzumab tirumotecan topline data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06074588 (Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06074588)) |
| May 2027 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06074588 (Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06074588)) |
| Jun to Sep 2027 | [LUMYKRAS™ (sotorasib) topline data readout](https://sec-api.dev/pdufa/sotorasib) | AMGN | Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT05920356 (A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05920356)) |
| June 2027 | [LUMYKRAS™ (sotorasib) primary completion](https://sec-api.dev/pdufa/sotorasib) | AMGN | Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT05920356 (A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05920356)) |
| October 2027 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT05801029 (A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05801029)) |
| Oct 2027 to Jan 2028 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer (NSCLC) | scheduled | "NCT05801029 (A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05801029)) |
| Nov 2027 to Feb 2028 | [Rina-s topline data readout](https://sec-api.dev/pdufa/rina-s) | GMAB | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07288177 (Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-22 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288177)) |
| November 2027 | [Rina-s primary completion](https://sec-api.dev/pdufa/rina-s) | GMAB | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07288177 (Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-22 (ESTIMATED); Lead Sponsor Genmab." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288177)) |
| Jan to Apr 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06170788 (Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06170788)) |
| January 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06170788 (Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06170788)) |
| Aug to Nov 2028 | [Sacituzumab tirumotecan topline data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06305754 (Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06305754)) |
| August 2028 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06305754 (Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06305754)) |
| Jan to Apr 2029 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer; NSCLC | scheduled | "NCT06422143 (Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06422143)) |
| Jan to Apr 2029 | [Datopotamab deruxtecan (dato-dxd) topline data readout](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) | AZN | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07291037 (Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07291037)) |
| January 2029 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer; NSCLC | scheduled | "NCT06422143 (Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06422143)) |
| January 2029 | [Datopotamab deruxtecan (dato-dxd) primary completion](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) | AZN | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07291037 (Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07291037)) |
| Dec 2029 to Mar 2030 | [REGN10597 topline data readout](https://sec-api.dev/pdufa/regn10597) | REGN | Non Small Cell Lung Cancer; NSCLC | scheduled | "NCT06465329 (A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-12-04 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465329)) |
| December 2029 | [REGN10597 primary completion](https://sec-api.dev/pdufa/regn10597) | REGN | Non Small Cell Lung Cancer; NSCLC | scheduled | "NCT06465329 (A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-12-04 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465329)) |
| Aug to Nov 2030 | [IBTROZI (taletrectinib) topline data readout](https://sec-api.dev/pdufa/taletrectinib) | NUVB | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07154706 (Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-30 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07154706)) |
| August 2030 | [IBTROZI (taletrectinib) primary completion](https://sec-api.dev/pdufa/taletrectinib) | NUVB | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07154706 (Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-30 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07154706)) |
| Sep to Dec 2030 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BMY | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07361497 (A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07361497)) |
| September 2030 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BMY | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT07361497 (A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07361497)) |

## Drugs

- [TEVIMBRA® (tislelizumab)](https://sec-api.dev/pdufa/tislelizumab) (ONC)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) (MRK)
- [LUMYKRAS™ (sotorasib)](https://sec-api.dev/pdufa/sotorasib) (AMGN)
- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib) (AZN)
- [Rina-s](https://sec-api.dev/pdufa/rina-s) (GMAB)
- [Datopotamab deruxtecan (dato-dxd)](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) (AZN)
- [REGN10597](https://sec-api.dev/pdufa/regn10597) (REGN)
- [IBTROZI (taletrectinib)](https://sec-api.dev/pdufa/taletrectinib) (NUVB)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/non-small-cell-lung-cancer-nsclc.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Non-small Cell Lung Cancer; NSCLC FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/non-small-cell-lung-cancer-nsclc

```bibtex
@misc{secapidev_indications_non_small_cell_lung_cancer_nsclc_20261116,
  title        = {Non-small Cell Lung Cancer; NSCLC FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/non-small-cell-lung-cancer-nsclc}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_non_small_cell_lung_cancer_nsclc_20261116","title":"Non-small Cell Lung Cancer; NSCLC FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/non-small-cell-lung-cancer-nsclc","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
